Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | RET | P07949 | 2/20 | 0.43 |
| ▸ | IDE | P14735 | 1/20 | 0.42 |
| ▸ | PRKAA2 | P54646 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | AR | P10275 | 5/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | PHGDH | O43175 | 1/20 | 0.38 |
| ▸ | SMO | Q99835 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2617802 | 1.00 | SMN1; SMN2 (0.43) | SMN1; SMN2HPGDRETIDEPRKAA2 | |
| SCHEMBL2119282 | 1.00 | SMN1; SMN2 (0.43) | SMN1; SMN2HPGDRETIDEPRKAA2 | |
| SCHEMBL2617866 | 0.92 | AR (0.46) | RETPRKAA2AR | |
| SCHEMBL2119410 | 0.92 | AR (0.46) | RETPRKAA2AR | |
| SCHEMBL2119470 | 0.91 | RET (0.41) | RETPRKAA2AR | |
| SCHEMBL2617801 | 0.91 | RET (0.41) | RETPRKAA2AR | |
| SCHEMBL2617867 | 0.91 | RET (0.41) | RETPRKAA2AR | |
| SCHEMBL2617832 | 0.91 | SMN1; SMN2 (0.51) | SMN1; SMN2HPGDRETIDEPRKAA2 | |
| SCHEMBL2120802 | 0.91 | SMN1; SMN2 (0.51) | SMN1; SMN2HPGDRETIDEPRKAA2 | |
| SCHEMBL2617777 | 0.91 | SMN1; SMN2 (0.51) | SMN1; SMN2HPGDRETIDEPRKAA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8507474-B2 | Anthelmintic agents and their use | INTERVET INTERNATIONAL B.V. (NL) | 2013-08-13 | — | — | US | disclosed |
| US-8507474-B2 | Anthelmintic agents and their use | INTERVET INTERNATIONAL B.V. (NL) | 2013-08-13 | — | — | US | disclosed |
| US-20120094981-A1 | ANTHELMINTIC AGENTS AND THEIR USE | INTERVET INTERNATIONAL B.V. (NL) | 2012-04-19 | — | — | US | disclosed |
| US-20120094981-A1 | ANTHELMINTIC AGENTS AND THEIR USE | INTERVET INTERNATIONAL B.V. (NL) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094981-A1 | ANTHELMINTIC AGENTS AND THEIR USE | ABCB11, ACHE, CMA1 | SMN1; SMN2 4488/4885HPGD 445/4885RET 4682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.